ロード中...
De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
The programmed cell death ligand-1 antibody, atezolizumab, is an immune checkpoint inhibitor approved for the treatment of various cancers. Herein, we describe a case of an 87-year-old man with advanced urothelial carcinoma. After surgery, atezolizumab was given. Subsequently, he developed generaliz...
保存先:
| 出版年: | Cureus |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cureus
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6713254/ https://ncbi.nlm.nih.gov/pubmed/31497433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.5002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|